Evidence map›Paper›PMID 39445504›Full record

ArticleFuture oncology (London, England)2024

Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.

Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jonathan KrellInstitute of Reproductive and Developmental Biology, Imperial College London, London, W12 0HS, UK.ORCID 0000-0002-9835-9227
Danielle ShawThe Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, L7 8YA, UK.
John McGraneSunrise Oncology Centre, Royal Cornwall Hospitals NHS Trust, Cornwall, TR1 3LJ, UK.ORCID 0000-0001-9371-3250
Andreas HartkopfDepartment of Women's Health, Universitätsklinikum Tübingen, Tübingen, 72076, Germany.
Ana HerreroDepartment of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain.ORCID 0000-0002-0229-137X
Cheng YeohQueen Alexandra Hospital, Portsmouth, PO6 3LY, UK.
Maria MasvidalMedical Oncology Department, Hospital Universitari Sant Joan de Reus, Tarragona, 43204, Spain.
Francesco RaspagliesiGynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy.ORCID 0000-0001-8953-1657
Whitney YorkGSK, Medical & Market Access Oncology Statistics, Philadelphia, PA 19426, USA.
Jeanne M SchilderGSK, Philadelphia, PA 19426, USA.
Barbara MascialinoGSK, Verona, 37135, Italy.
Eleanor McDermottGSK, Stevenage, SG1 2NY, UK.
Linda KalilaniGSK, Research Triangle, Durham, NC 27701, USA.
Lars HankerDepartment of Gynecology & Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, 23538, Germany.ORCID 0000-0001-6697-018X

Funding

GlaxoSmithKline N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ovarian NeoplasmsAdultAgedAged, 80 and overCytoreduction Surgical ProceduresDisease ProgressionEuropeFemaleHumansMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesRisk Factorshigh-risk factorsovarianovarian canceroverall survivalprogression-free survivalreal-world evidencesurvival

Identifiers

PMID39445504
PMCPMC11778796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.